| Literature DB >> 30272964 |
Ingrid Buchler1, Daniel Akuma1, Vinh Au1, Gregory Carr1,2, Pablo de León1, Michael DePasquale1, Glen Ernst1, Yifang Huang1, Martha Kimos1, Anna Kolobova1, Michael Poslusney1, Huijun Wei1,2, Dominique Swinnen3, Florian Montel3, Florence Moureau3, Emilie Jigorel3, Monika-Sarah E D Schulze4, Martyn Wood3, James C Barrow1,2.
Abstract
A series of 8-hydroxy quinolines were identified as potent inhibitors of catechol O-methyltransferase (COMT) with selectivity for the membrane-bound form of the enzyme. Small substituents at the 7-position of the quinoline were found to increase metabolic stability without sacrificing potency. Compounds with good pharmacokinetics and brain penetration were identified and demonstrated in vivo modulation of dopamine metabolites in the brain. An X-ray cocrystal structure of compound 21 in the S-COMT active site shows chelation of the active site magnesium similar to catechol-based inhibitors. These compounds should prove useful for treatment of many neurological and psychiatric conditions associated with compromised cortical dopamine signaling.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30272964 PMCID: PMC6398604 DOI: 10.1021/acs.jmedchem.8b01126
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446